Exploiting poly(I:C) to induce cancer cell apoptosis

References

• Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-76. doi:10.1146/annurev.immunol.21.120601.141126
   PubMed Web of Science ®Google Scholar
• Tamassia N, Le M, V, Rossato M, Donini M, McCartney S, Calzetti F, Colonna M, Bazzoni F, Cassatella MA. Activation of an immunoregulatory and antiviral gene expression program in poly(I:C)-transfected human neutrophils. J Immunol. 2008;181(9):6563-73. doi:10.4049/jimmunol.181.9.6563
   PubMed Web of Science ®Google Scholar
• Wesch D, Beetz S, Oberg HH, Marget M, Krengel K, Kabelitz D. Direct costimulatory effect of TLR3 ligand poly(I:C) on human gamma delta T lymphocytes. J Immunol. 2006;176(3):1348-54. doi:10.4049/jimmunol.176.3.1348
   PubMed Web of Science ®Google Scholar
• Kang J, Demaria S, Formenti S. Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer. 2016;4:51. eCollection;%2016.:51-0156. doi:10.1186/s40425-016-0156-7
   PubMed Web of Science ®Google Scholar
• Le Noci V, Tortoreto M, Gulino A, Storti C, Bianchi F, Zaffaroni N, Tripodo C, Tagliabue E, Balsari A, Sfondrini L. Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment. OncoImmunology. 2015;4(10):e1040214. doi:10.1080/2162402X.2015.1040214
   PubMed Web of Science ®Google Scholar
• Le Noci V, Sommariva M, Tortoreto M, Zaffaroni N, Campiglio M, Tagliabue E, Balsari A, Sfondrini L. Reprogramming the lung microenvironment by inhaled immunotherapt forsters immune destruction of tumor. OncoImmunology. 2016;5:e1234571. doi:10.1080/2162402X.2016.1234571
   PubMed Web of Science ®Google Scholar
• Shime H, Matsumoto M, Oshiumi H, Tanaka S, Nakane A, Iwakura Y, Tahara H, Inoue N, Seya T. Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci U S A. 2012;109(6):2066-71. doi:10.1073/pnas.1113099109
   PubMed Web of Science ®Google Scholar
• Estornes Y, Micheau O, Renno T, Lebecque S. Dual role of TLR3 in inflammation and cancer cell apoptosis. In: Siregar Y, editor. Oncogene and Cancer - from Bench to Clinic. Novi Sad (Croatia). INTECH; 2013. p. 247-70.
   Google Scholar
• Oshiumi H, Okamoto M, Fujii K, Kawanishi T, Matsumoto M, Koike S, Seya T. The TLR3/TICAM-1 pathway is mandatory for innate immune responses to poliovirus infection. J Immunol. 2011;187(10):5320-7. doi:10.4049/jimmunol.1101503
   PubMed Web of Science ®Google Scholar
• Abe Y, Fujii K, Nagata N, Takeuchi O, Akira S, Oshiumi H, Matsumoto M, Seya T, Koike S. The toll-like receptor 3-mediated antiviral response is important for protection against poliovirus infection in poliovirus receptor transgenic mice. J Virol. 2012;86(1):185-94. doi:10.1128/JVI.05245-11
   PubMed Web of Science ®Google Scholar
• Negishi H, Osawa T, Ogami K, Ouyang X, Sakaguchi S, Koshiba R, Yanai H, Seko Y, Shitara H, Bishop K, et al. A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity. Proc Natl Acad Sci U S A. 2008;105(51):20446-51. doi:10.1073/pnas.0810372105
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Kikkawa S, Kohase M, Miyake K, Seya T. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun. 2002;293(5):1364-9. doi:10.1016/S0006-291X(02)00380-7
   PubMed Web of Science ®Google Scholar
• Pirher N, Pohar J, Mancek-Keber M, Bencina M, Jerala R. Activation of cell membrane-localized Toll-like receptor 3 by siRNA. Immunol Lett. 2017;(17):10
   Google Scholar
• Itoh K, Watanabe A, Funami K, Seya T, Matsumoto M. The clathrin-mediated endocytic pathway participates in dsRNA-induced IFN-beta production. J Immunol. 2008;181(8):5522-9. doi:10.4049/jimmunol.181.8.5522
   PubMed Web of Science ®Google Scholar
• Watanabe A, Tatematsu M, Saeki K, Shibata S, Shime H, Yoshimura A, Obuse C, Seya T, Matsumoto M. Raftlin is involved in the nucleocapture complex to induce poly(I:C)-mediated TLR3 activation. J Biol Chem. 2011;286(12):10702-11. doi:10.1074/jbc.M110.185793
   PubMed Web of Science ®Google Scholar
• Singh D, Qi R, Jordan JL, San ML, Kao CC. The human antimicrobial peptide LL-37, but not the mouse ortholog, mCRAMP, can stimulate signaling by poly(I:C) through a FPRL1-dependent pathway. J Biol Chem. 2013;288(12):8258-68. doi:10.1074/jbc.M112.440883
   PubMed Web of Science ®Google Scholar
• Chattopadhyay S, Sen GC. dsRNA-activation of TLR3 and RLR signaling: gene induction-dependent and independent effects. J Interferon Cytokine Res. 2014;34(6):427-36. doi:10.1089/jir.2014.0034
   PubMed Web of Science ®Google Scholar
• Yamashita M, Chattopadhyay S, Fensterl V, Saikia P, Wetzel JL, Sen GC. Epidermal growth factor receptor is essential for Toll-like receptor 3 signaling. Sci Signal. 2012;5(233):ra50. doi:10.1126/scisignal.2002581
   PubMed Web of Science ®Google Scholar
• Dunne A, O'Neill LA. Adaptor usage and Toll-like receptor signaling specificity. FEBS Lett. 2005;579(15):3330-5. doi:10.1016/j.febslet.2005.04.024
   PubMed Web of Science ®Google Scholar
• Takeda K, Akira S. TLR signaling pathways. Semin Immunol. 2004;16(1):3-9. doi:10.1016/j.smim.2003.10.003
   PubMed Web of Science ®Google Scholar
• Jiang Z, Mak TW, Sen G, Li X. Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta. Proc Natl Acad Sci U S A. 2004;101(10):3533-8. doi:10.1073/pnas.0308496101
   PubMed Web of Science ®Google Scholar
• Sasai M, Oshiumi H, Matsumoto M, Inoue N, Fujita F, Nakanishi M, Seya T. Cutting Edge: NF-kappaB-activating kinase-associated protein 1 participates in TLR3/Toll-IL-1 homology domain-containing adapter molecule-1-mediated IFN regulatory factor 3 activation. J Immunol. 2005;174(1):27-30. doi:10.4049/jimmunol.174.1.27
   PubMed Web of Science ®Google Scholar
• Meylan E, Burns K, Hofmann K, Blancheteau V, Martinon F, Kelliher M, Tschopp J. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat Immunol. 2004;5(5):503-7. doi:10.1038/ni1061
   PubMed Web of Science ®Google Scholar
• Cusson-Hermance N, Khurana S, Lee TH, Fitzgerald KA, Kelliher MA. Rip1 mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-{kappa}B activation but does not contribute to interferon regulatory factor 3 activation. J Biol Chem. 2005;280:36560-6. doi:10.1074/jbc.M506831200
   PubMed Web of Science ®Google Scholar
• Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, Maniatis T. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol. 2003;4(5):491-6. doi:10.1038/ni921
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Seya T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev. 2008;60(7):805-12. doi:10.1016/j.addr.2007.11.005
   PubMed Web of Science ®Google Scholar
• Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol. 2006;176(8):4894-901. doi:10.4049/jimmunol.176.8.4894
   PubMed Web of Science ®Google Scholar
• Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P. Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res. 2007;13(15 Pt 1):4565-74. doi:10.1158/1078-0432.CCR-07-0274
   PubMed Web of Science ®Google Scholar
• Estornes Y, Toscano F, Virard F, Jacquemin G, Pierrot A, Vanbervliet B, Bonnin M, Lalaoui N, Mercier-Gouy P, Pacheco Y, et al. dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8. Cell Death Differ. 2012;19(9):1482-94. doi:10.1038/cdd.2012.22
   PubMed Web of Science ®Google Scholar
• Friboulet L, Pioche-Durieu C, Rodriguez S, Valent A, Souquere S, Ripoche H, Khabir A, Tsao SW, Bosq J, Lo KW, et al. Recurrent overexpression of c-IAP2 in EBV-associated nasopharyngeal carcinomas: critical role in resistance to Toll-like receptor 3-mediated apoptosis. Neoplasia. 2008;10(11):1183-94. doi:10.1593/neo.08590
   PubMed Web of Science ®Google Scholar
• Weber A, Kirejczyk Z, Besch R, Potthoff S, Leverkus M, Hacker G. Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells. Cell Death Differ. 2010;17(6):942-51. doi:10.1038/cdd.2009.190
   PubMed Web of Science ®Google Scholar
• Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M, Cain K, MacFarlane M, Hacker G, Leverkus M. cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell. 2011;43(3):449-63. doi:10.1016/j.molcel.2011.06.011
   PubMed Web of Science ®Google Scholar
• Kaiser WJ, Offermann MK. Apoptosis induced by the toll-like receptor adaptor TRIF is dependent on its receptor interacting protein homotypic interaction motif. J Immunol. 2005;174(8):4942-52. doi:10.4049/jimmunol.174.8.4942
   PubMed Web of Science ®Google Scholar
• Kaiser WJ, Upton JW, Long AB, Livingston-Rosanoff D, ey-Bauer LP, Hakem R, Caspary T, Mocarski ES. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature. 2011;471(7338):368-72. doi:10.1038/nature09857
   PubMed Web of Science ®Google Scholar
• Oberst A, Dillon CP, Weinlich R, McCormick LL, Fitzgerald P, Pop C, Hakem R, Salvesen GS, Green DR. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature. 2011;471(7338):363-7. doi:10.1038/nature09852
   PubMed Web of Science ®Google Scholar
• Paone A, Starace D, Galli R, Padula F, De CP, Filippini A, Ziparo E, Riccioli A. Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis. 2008;29(7):1334-42. doi:10.1093/carcin/bgn149
   PubMed Web of Science ®Google Scholar
• Sun R, Zhang Y, Lv Q, Liu B, Jin M, Zhang W, He Q, Deng M, Liu X, Li G, et al. Toll-like receptor 3 (TLR3) induces apoptosis via death receptors and mitochondria by up-regulating the transactivating p63 isoform alpha (TAP63alpha). J Biol Chem. 2011;286(18):15918-28. doi:10.1074/jbc.M110.178798
   PubMed Web of Science ®Google Scholar
• Avril T, de TM, Leberre C, Quillien V. Not all polyriboinosinic-polyribocytidylic acids (Poly I:C) are equivalent for inducing maturation of dendritic cells: implication for alpha-type-1 polarized DCs. J Immunother. 2009;32(4):353-62. doi:10.1097/CJI.0b013e31819d29bf
   PubMed Web of Science ®Google Scholar
• McNally B, Willette M, Ye F, Partida-Sanchez S, Flano E. Intranasal administration of dsRNA analog poly(I:C) induces interferon-alpha receptor-dependent accumulation of antigen experienced T cells in the airways. PLoS One. 2012;7(12):e51351. doi:10.1371/journal.pone.0051351
   PubMed Web of Science ®Google Scholar
• Yoneda K, Sugimoto K, Shiraki K, Tanaka J, Beppu T, Fuke H, Yamamoto N, Masuya M, Horie R, Uchida K, et al. Dual topology of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: differential signaling mechanisms of TLR3-induced NF-kappaB activation and apoptosis. Int J Oncol. 2008;33(5):929-36.
   PubMed Web of Science ®Google Scholar
• Chew V, Tow C, Huang C, Bard-Chapeau E, Copeland NG, Jenkins NA, Weber A, Lim KH, Toh HC, Heikenwalder M, et al. Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients. J Natl Cancer Inst. 2012;104(23):1796-807. doi:10.1093/jnci/djs436
   PubMedGoogle Scholar
• Chew V, Abastado JP. Immunomodulation of the tumor microenvironment by Toll-like receptor-3 (TLR3) ligands. Oncoimmunology. 2013;2(4):e23493. doi:10.4161/onci.23493
   PubMed Web of Science ®Google Scholar
• Fernandez-Garcia B, Eiro N, Gonzalez-Reyes S, Gonzalez L, Aguirre A, Gonzalez LO, Del Casar JM, Garcia-Muniz JL, Vizoso FJ. Clinical significance of toll-like receptor 3, 4, and 9 in gastric cancer. J Immunother. 2014;37(2):77-83. doi:10.1097/CJI.0000000000000016
   PubMed Web of Science ®Google Scholar
• Gonzalez-Reyes S, Marin L, Gonzalez L, Gonzalez LO, Del Casar JM, Lamelas ML, Gonzalez-Quintana JM, Vizoso FJ. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer. 2010;10:665. doi:10.1186/1471-2407-10-665
   PubMed Web of Science ®Google Scholar
• Salaun B, Zitvogel L, sselin-Paturel C, Morel Y, Chemin K, Dubois C, Massacrier C, Conforti R, Chenard MP, Sabourin JC, et al. TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res. 2011;71(5):1607-14. doi:10.1158/0008-5472.CAN-10-3490
   PubMed Web of Science ®Google Scholar
• Hsu WM, Huang CC, Wu PY, Lee H, Huang MC, Tai MH, Chuang JH. Toll-like receptor 3 expression inhibits cell invasion and migration and predicts a favorable prognosis in neuroblastoma. Cancer Lett. 2013;336(2):338-46. doi:10.1016/j.canlet.2013.03.024
   PubMed Web of Science ®Google Scholar
• Goto Y, Arigami T, Kitago M, Nguyen SL, Narita N, Ferrone S, Morton DL, Irie RF, Hoon DS. Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther. 2008;7(11):3642-53. doi:10.1158/1535-7163.MCT-08-0582
   PubMed Web of Science ®Google Scholar
• Chuang JH, Chuang HC, Huang CC, Wu CL, Du YY, Kung ML, Chen CH, Chen SC, Tai MH. Differential toll-like receptor 3 (TLR3) expression and apoptotic response to TLR3 agonist in human neuroblastoma cells. J Biomed Sci. 2011;18:65. doi:10.1186/1423-0127-18-65
   PubMed Web of Science ®Google Scholar
• Tissari J, Siren J, Meri S, Julkunen I, Matikainen S. IFN-alpha enhances TLR3-mediated antiviral cytokine expression in human endothelial and epithelial cells by up-regulating TLR3 expression. J Immunol. 2005;174(7):4289-94. doi:10.4049/jimmunol.174.7.4289
   PubMed Web of Science ®Google Scholar
• Tanabe M, Kurita-Taniguchi M, Takeuchi K, Takeda M, Ayata M, Ogura H, Matsumoto M, Seya T. Mechanism of up-regulation of human Toll-like receptor 3 secondary to infection of measles virus-attenuated strains. Biochem Biophys Res Commun. 2003;311(1):39-48. doi:10.1016/j.bbrc.2003.09.159
   PubMed Web of Science ®Google Scholar
• Taura M, Fukuda R, Suico MA, Eguma A, Koga T, Shuto T, Sato T, Morino-Koga S, Kai H. TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis. Cancer Sci. 2010;101(7):1610-7. doi:10.1111/j.1349-7006.2010.01567.x
   PubMed Web of Science ®Google Scholar
• Papageorgiou A, Dinney CP, Mcconkey DJ. Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells. Cancer Biol Ther. 2007;6(6):872-9. doi:10.4161/cbt.6.6.4088
   PubMed Web of Science ®Google Scholar
• Faustino-Rocha AI, Ferreira R, Gama A, Oliveira PA, Ginja M. Antihistamines as promising drugs in cancer therapy. Life Sci. 2017;172:27-41. Epub;%2016 Dec 14.:27-41. doi:10.1016/j.lfs.2016.12.008
   PubMed Web of Science ®Google Scholar
• Hou YF, Zhou YC, Zheng XX, Wang HY, Fu YL, Fang ZM, He SH. Modulation of expression and function of Toll-like receptor 3 in A549 and H292 cells by histamine. Mol Immunol. 2006;43(12):1982-92. doi:10.1016/j.molimm.2005.11.013
   PubMed Web of Science ®Google Scholar
• Jang S, Park JS, Won YH, Yun SJ, Kim SJ. The Expression of Toll-Like Receptors (TLRs) in Cultured Human Skin Fibroblast is Modulated by Histamine. Chonnam Med J. 2012;48(1):7-14. doi:10.4068/cmj.2012.48.1.7
   PubMedGoogle Scholar
• Merves J, Chandramouleeswaran PM, Benitez AJ, Muir AB, Lee AJ, Lim DM, Dods K, Mehta I, Ruchelli ED, Nakagawa H, et al. Altered esophageal histamine receptor expression in Eosinophilic Esophagitis (EoE): implications on disease pathogenesis. PLoS One. 2015;10(2):e0114831. doi:10.1371/journal.pone.0114831
   PubMed Web of Science ®Google Scholar
• Funayama H, Huang L, Asada Y, Endo Y, Takada H. Enhanced induction of a histamine-forming enzyme, histidine decarboxylase, in mice primed with NOD1 or NOD2 ligand in response to various Toll-like receptor agonists. Innate Immun. 2010;16(4):265-72. doi:10.1177/1753425909341070
   PubMed Web of Science ®Google Scholar
• Kimura G, Ueda K, Eto S, Watanabe Y, Masuko T, Kusama T, Barnes PJ, Ito K, Kizawa Y. Toll-like receptor 3 stimulation causes corticosteroid-refractory airway neutrophilia and hyperresponsiveness in mice. Chest. 2013;144(1):99-105. doi:10.1378/chest.12-2610
   PubMed Web of Science ®Google Scholar
• Larousserie F, Bardel E, Pflanz S, Arnulf B, Lome-Maldonado C, Hermine O, Bregeaud L, Perennec M, Brousse N, Kastelein R, et al. Analysis of interleukin-27 (EBI3/p28) expression in Epstein-Barr virus- and human T-cell leukemia virus type 1-associated lymphomas: heterogeneous expression of EBI3 subunit by tumoral cells. Am J Pathol. 2005;166(4):1217-28. doi:10.1016/S0002-9440(10)62340-1
   PubMed Web of Science ®Google Scholar
• Lucas S, Ghilardi N, Li J, de Sauvage FJ. IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms. Proc Natl Acad Sci U S A. 2003;100(25):15047-52. doi:10.1073/pnas.2536517100
   PubMed Web of Science ®Google Scholar
• Seregni E, Botti C, Massaron S, Lombardo C, Capobianco A, Bogni A, Bombardieri E. Structure, function and gene expression of epithelial mucins. Tumori. 1997;83(3):625-32.
   PubMed Web of Science ®Google Scholar
• Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia. 2001;6(3):339-53. doi:10.1023/A:1011379725811
   PubMed Web of Science ®Google Scholar
• Apostolopoulos V, Stojanovska L, Gargosky SE. MUC1 (CD227): a multi-tasked molecule. Cell Mol Life Sci. 2015;72(23):4475-500. doi:10.1007/s00018-015-2014-z
   PubMed Web of Science ®Google Scholar
• Sousa AM, Grandgenett PM, David L, Almeida R, Hollingsworth MA, Santos-Silva F. Reflections on MUC1 glycoprotein: the hidden potential of isoforms in carcinogenesis. APMIS. 2016;124(11):913-24. doi:10.1111/apm.12587
   PubMed Web of Science ®Google Scholar
• Hilkens J, Wesseling J, Vos HL, Storm J, Boer B, van der Valk SW, Maas MC. Involvement of the cell surface-bound mucin, episialin/MUC1, in progression of human carcinomas. Biochem Soc Trans. 1995;23(4):822-6. doi:10.1042/bst0230822
   PubMed Web of Science ®Google Scholar
• Sipaul F, Birchall M, Corfield A. What role do mucins have in the development of laryngeal squamous cell carcinoma? A systematic review. Eur Arch Otorhinolaryngol. 2011;268(8):1109-17. doi:10.1007/s00405-011-1617-8
   PubMed Web of Science ®Google Scholar
• Paszkiewicz-Gadek A, Porowska H, Anchim T, Wolczynski S, Gindzienski A. Biosynthesis of MUC1 mucin in human endometrial adenocarcinoma is modulated by estradiol and tamoxifen. Gynecol Endocrinol. 2003;17(1):37-44. doi:10.1080/gye.17.1.37.44
   PubMed Web of Science ®Google Scholar
• Weissenbacher T, Kuhn C, Mayr D, Pavlik R, Friese K, Scholz C, Jeschke U, Ditsch N, Dian D. Expression of mucin-1, galectin-1 and galectin-3 in human leiomyosarcoma in comparison to leiomyoma and myometrium. Anticancer Res. 2011;31(2):451-7.
   PubMed Web of Science ®Google Scholar
• Brossart P, Schneider A, Dill P, Schammann T, Grunebach F, Wirths S, Kanz L, Buhring HJ, Brugger W. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 2001;61(18):6846-50.
   PubMed Web of Science ®Google Scholar
• Teruya-Feldstein J, Donnelly GB, Goy A, Hegde A, Nanjangud G, Qin J, Thaler H, Gilles F, Dyomin VG, Lloyd KO, et al. MUC-1 mucin protein expression in B-cell lymphomas. Appl Immunohistochem Mol Morphol. 2003;11(1):28-32. doi:10.1097/00129039-200303000-00005
   PubMedGoogle Scholar
• Kato K, Lillehoj EP, Kim KC. MUC1 regulates epithelial inflammation and apoptosis by PolyI:C through inhibition of Toll/IL-1 receptor-domain-containing adapter-inducing IFN-beta (TRIF) recruitment to Toll-like receptor 3. Am J Respir Cell Mol Biol. 2014;51(3):446-54. doi:10.1165/rcmb.2014-0018OC
   PubMed Web of Science ®Google Scholar
• Chen N, Chen X, Huang R, Zeng H, Gong J, Meng W, Lu Y, Zhao F, Wang L, Zhou Q. BCL-xL is a target gene regulated by hypoxia-inducible factor-1{alpha}. J Biol Chem. 2009;284(15):10004-12. doi:10.1074/jbc.M805997200
   PubMed Web of Science ®Google Scholar
• Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem. 2006;281(36):25903-14. doi:10.1074/jbc.M603414200
   PubMed Web of Science ®Google Scholar
• Piret JP, Minet E, Cosse JP, Ninane N, Debacq C, Raes M, Michiels C. Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis. J Biol Chem. 2005;280(10):9336-44. doi:10.1074/jbc.M411858200
   PubMed Web of Science ®Google Scholar
• Blouin CC, Page EL, Soucy GM, Richard DE. Hypoxic gene activation by lipopolysaccharide in macrophages: implication of hypoxia-inducible factor 1alpha. Blood. 2004;103(3):1124-30. doi:10.1182/blood-2003-07-2427
   PubMed Web of Science ®Google Scholar
• Nicholas SA, Sumbayev VV. The involvement of hypoxia-inducible factor 1 alpha in Toll-like receptor 7/8-mediated inflammatory response. Cell Res. 2009;19(8):973-83. doi:10.1038/cr.2009.44
   PubMed Web of Science ®Google Scholar
• Ramanathan M, Luo W, Csoka B, Hasko G, Lukashev D, Sitkovsky MV, Leibovich SJ. Differential regulation of HIF-1alpha isoforms in murine macrophages by TLR4 and adenosine A(2A) receptor agonists. J Leukoc Biol. 2009;86(3):681-9. doi:10.1189/jlb.0109021
   PubMed Web of Science ®Google Scholar
• Paone A, Galli R, Gabellini C, Lukashev D, Starace D, Gorlach A, De CP, Ziparo E, Del BD, Sitkovsky MV, et al. Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 alpha. Neoplasia. 2010;12(7):539-49. doi:10.1593/neo.92106
   PubMed Web of Science ®Google Scholar
• Chaika NV, Gebregiworgis T, Lewallen ME, Purohit V, Radhakrishnan P, Liu X, Zhang B, Mehla K, Brown RB, Caffrey T, et al. MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proc Natl Acad Sci U S A. 2012;109(34):13787-92. doi:10.1073/pnas.1203339109
   PubMed Web of Science ®Google Scholar
• Kuefer R, Day KC, Kleer CG, Sabel MS, Hofer MD, Varambally S, Zorn CS, Chinnaiyan AM, Rubin MA, Day ML. ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. Neoplasia. 2006;8(4):319-29. doi:10.1593/neo.05682
   PubMed Web of Science ®Google Scholar
• Carl-McGrath S, Lendeckel U, Ebert M, Roessner A, Rocken C. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol. 2005;26(1):17-24.
   PubMed Web of Science ®Google Scholar
• Ortiz RM, Karkkainen I, Huovila AP. Aberrant alternative exon use and increased copy number of human metalloprotease-disintegrin ADAM15 gene in breast cancer cells. Genes Chromosomes Cancer. 2004;41(4):366-78. doi:10.1002/gcc.20102
   PubMed Web of Science ®Google Scholar
• Lorenzatti Hiles G, Bucheit A, Rubin JR, Hayward A, Cates AL, Day KC, El-Sawy L, Kunju LP, Daignault S, Lee CT, et al. ADAM15 is functionally associated with the metastatic progression of human bladder cancer. PLoS One. 2016;11(3):e0150138. doi:10.1371/journal.pone.0150138
   PubMed Web of Science ®Google Scholar
• Dong DD, Zhou H, Li G. ADAM15 targets MMP9 activity to promote lung cancer cell invasion. Oncol Rep. 2015;34(5):2451-60. doi:10.3892/or.2015.4203
   PubMed Web of Science ®Google Scholar
• Ahmed S, Maratha A, Butt AQ, Shevlin E, Miggin SM. TRIF-mediated TLR3 and TLR4 signaling is negatively regulated by ADAM15. J Immunol. 2013;190(5):2217-28. doi:10.4049/jimmunol.1201630
   PubMed Web of Science ®Google Scholar
• Saleem M, Qadir MI, Perveen N, Ahmad B, Saleem U, Irshad T, Ahmad B. Inhibitors of apoptotic proteins: new targets for anticancer therapy. Chem Biol Drug Des. 2013;82(3):243-51. doi:10.1111/cbdd.12176
   PubMed Web of Science ®Google Scholar
• Bertrand MJ, Lippens S, Staes A, Gilbert B, Roelandt R, De Medts J, Gevaert K, Declercq W, Vandenabeele P. cIAP1/2 are direct E3 ligases conjugating diverse types of ubiquitin chains to receptor interacting proteins kinases 1 to 4 (RIP1-4). PLoS One. 2011;6(9):e22356. doi:10.1371/journal.pone.0022356
   PubMed Web of Science ®Google Scholar
• Damgaard RB, Nachbur U, Yabal M, Wong WW, Fiil BK, Kastirr M, Rieser E, Rickard JA, Bankovacki A, Peschel C, et al. The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. Mol Cell. 2012;46(6):746-58. doi:10.1016/j.molcel.2012.04.014
   PubMed Web of Science ®Google Scholar
• Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K, Fairbrother WJ, Vucic D. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem. 2008;283(36):24295-9. doi:10.1074/jbc.C800128200
   PubMed Web of Science ®Google Scholar
• Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, Gillard JW, Jaquith JB, Morris SJ, Barker PA. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell. 2008;30(6):689-700. doi:10.1016/j.molcel.2008.05.014
   PubMed Web of Science ®Google Scholar
• Conte D, Holcik M, Lefebvre CA, Lacasse E, Picketts DJ, Wright KE, Korneluk RG. Inhibitor of apoptosis protein cIAP2 is essential for lipopolysaccharide-induced macrophage survival. Mol Cell Biol. 2006;26(2):699-708. doi:10.1128/MCB.26.2.699-708.2006
   PubMed Web of Science ®Google Scholar
• Hassan M, Watari H, buAlmaaty A, Ohba Y, Sakuragi N. Apoptosis and molecular targeting therapy in cancer. Biomed Res Int. 2014;2014:150845. Epub;%2014 Jun 12.:150845. doi:10.1155/2014/150845
   PubMed Web of Science ®Google Scholar
• Bai L, Smith DC, Wang S. Small-molecule SMAC mimetics as new cancer therapeutics. Pharmacol Ther. 2014;144(1):82-95. doi:10.1016/j.pharmthera.2014.05.007
   PubMed Web of Science ®Google Scholar
• Verillaud B, Gressette M, Morel Y, Paturel C, Herman P, Lo KW, Tsao SW, Wassef M, Jimenez-Pailhes AS, Busson P. Toll-like receptor 3 in Epstein-Barr virus-associated nasopharyngeal carcinomas: consistent expression and cytotoxic effects of its synthetic ligand poly(A:U) combined to a Smac-mimetic. Infect Agent Cancer. 2012;7(1):36-7. doi:10.1186/1750-9378-7-36
   PubMed Web of Science ®Google Scholar
• Bernardo AR, Cosgaya JM, Aranda A, Jimenez-Lara AM. Synergy between RA and TLR3 promotes type I IFN-dependent apoptosis through upregulation of TRAIL pathway in breast cancer cells. Cell Death Dis. 2013;4:e479. doi:10.1038/cddis.2013.5
   PubMed Web of Science ®Google Scholar
• Bernardo AR, Cosgaya JM, Aranda A, Jimenez-Lara AM. Pro-apoptotic signaling induced by Retinoic acid and dsRNA is under the control of Interferon Regulatory Factor-3 in breast cancer cells. Apoptosis. 2017;22(7):920-32. doi:10.1007/s10495-017-1377-z
   PubMed Web of Science ®Google Scholar
• Galli R, Paone A, Fabbri M, Zanesi N, Calore F, Cascione L, Acunzo M, Stoppacciaro A, Tubaro A, Lovat F, et al. Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RARbeta and tumor regression. Proc Natl Acad Sci U S A. 2013;110(24):9812-7. doi:10.1073/pnas.1304610110
   PubMed Web of Science ®Google Scholar
• Weiss R, Sachet M, Zinngrebe J, Aschacher T, Krainer M, Hegedus B, Walczak H, Bergmann M. IL-24 sensitizes tumor cells to TLR3-mediated apoptosis. Cell Death Differ. 2013;20(6):823-33. doi:10.1038/cdd.2013.15
   PubMed Web of Science ®Google Scholar
• Hu CW, Yin GF, Wang XR, Ren BW, Zhang WG, Bai QL, Lv YM, Li WL, Zhao WQ. IL-24 Induces Apoptosis via Upregulation of RNA-Activated Protein Kinase and Enhances Temozolomide-Induced Apoptosis in Glioma Cells. Oncol Res. 2014;22(3):159-65. doi:10.3727/096504015X14298122915628
   PubMed Web of Science ®Google Scholar
• Taura M, Eguma A, Suico MA, Shuto T, Koga T, Komatsu K, Komune T, Sato T, Saya H, Li JD, et al. p53 regulates Toll-like receptor 3 expression and function in human epithelial cell lines. Mol Cell Biol. 2008;28(21):6557-67. doi:10.1128/MCB.01202-08
   PubMed Web of Science ®Google Scholar
• Shatz M, Menendez D, Resnick MA. The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells. Cancer Res. 2012;72(16):3948-57. doi:10.1158/0008-5472.CAN-11-4134
   PubMed Web of Science ®Google Scholar
• Menendez D, Lowe JM, Snipe J, Resnick MA. Ligand dependent restoration of human TLR3 signaling and death in p53 mutant cells. Oncotarget. 2016;7(38):61630-61642. doi:10.18632/oncotarget.11210
   PubMed Web of Science ®Google Scholar
• Harashima N, Minami T, Uemura H, Harada M. Transfection of poly(I:C) can induce reactive oxygen species-triggered apoptosis and interferon-beta-mediated growth arrest in human renal cell carcinoma cells via innate adjuvant receptors and the 2–5A system. Mol Cancer. 2014;13:217. doi:10.1186/1476-4598-13-217
   PubMed Web of Science ®Google Scholar
• Pang LY, Scott M, Hayward RL, Mohammed H, Whitelaw CB, Smith GC, Hupp TR. p21(WAF1) is component of a positive feedback loop that maintains the p53 transcriptional program. Cell Cycle. 2011;10(6):932-50. doi:10.4161/cc.10.6.15012
   PubMed Web of Science ®Google Scholar
• Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, Selivanova G. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med. 2004;10(12):1321-8. doi:10.1038/nm1146
   PubMed Web of Science ®Google Scholar
• Zhao CY, Grinkevich VV, Nikulenkov F, Bao W, Selivanova G. Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA. Cell Cycle. 2010;9(9):1847-55. doi:10.4161/cc.9.9.11545
   PubMed Web of Science ®Google Scholar
• Yang A, Zhu Z, Kapranov P, McKeon F, Church GM, Gingeras TR, Struhl K. Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells. Mol Cell. 2006;24(4):593-602. doi:10.1016/j.molcel.2006.10.018
   PubMed Web of Science ®Google Scholar
• Su X, Chakravarti D, Flores ER. p63 steps into the limelight: crucial roles in the suppression of tumorigenesis and metastasis. Nat Rev Cancer. 2013;13(2):136-43. doi:10.1038/nrc3446
   PubMed Web of Science ®Google Scholar
• Sfondrini L, Sommariva M, Tortoreto M, Meini A, Piconese S, Calvaruso M, Van RN, Bonecchi, R, Zaffaroni N, Colombo MP, et al. Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases. Int J Cancer. 2013;133:383-93. doi:10.1002/ijc.28028
   PubMed Web of Science ®Google Scholar
• De Cesare A, Sfondrini L, Pennati M, De Marco C, Motta V, Tagliabue E, Deraco M, Balsari A, Zaffaroni N. CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts. J Transl Med. 2016;14:25. doi:10.1186/s12967-016-0781-4
   PubMed Web of Science ®Google Scholar
• Sommariva M, De Cecco L, De Cesare M, Sfondrini L, Ménard S, Melani C, Delia D, Zaffaroni N, Pratesi G, Uva V, et al. TLR9-agonists oppositely modulate DNA-repair genes in tumor vesus immune cells and ehance chemotherapy effects. Cancer Res. 2011;71:6382-90. doi:10.1158/0008-5472.CAN-11-1285
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lin A, Sui Q, Zhang C, Tian Z, Zhang J. Phosphorothioate modification of the TLR9 ligand CpG ODN inhibits poly(I:C)-induced apoptosis of hepatocellular carcinoma by entry blockade. Cancer Lett. 2014;355(1):76-84. doi:10.1016/j.canlet.2014.09.013
   PubMed Web of Science ®Google Scholar
• Gambara G, Desideri M, Stoppacciaro A, Padula F, De CP, Starace D, Tubaro A, Del BD, Filippini A, Ziparo E, et al. TLR3 engagement induces IRF-3-dependent apoptosis in androgen-sensitive prostate cancer cells and inhibits tumour growth in vivo. J Cell Mol Med. 2015;19(2):327-39. doi:10.1111/jcmm.12379
   PubMed Web of Science ®Google Scholar
• Wang S, Liu D, Jin R, Zhu Y, Xu A. Differential responses of normal human melanocytes to intra- and extracellular dsRNA. DNA Cell Biol. 2015;34(6):391-9. doi:10.1089/dna.2014.2711
   PubMed Web of Science ®Google Scholar